© 2003 by Oxford University Press
Journal of the National Cancer Institute Monographs, No. 31, 111-116,
2003
© 2003 Oxford University Press
ARTICLE |
Chapter 16: Prophylactic Human Papillomavirus Vaccines
Author affiliations: D. R. Lowy, Laboratory of Cellular Oncology, National Cancer Institute, National Institutes of Health, Bethesda, MD; I. H. Frazer, Centre for Immunology and Cancer Research, University of Queensland, Princess Alexandra Hospital, Brisbane, Queensland 4102, Australia (e-mail: ifrazer{at}medicine.pa.uq.edu.au).
Correspondence to: Douglas R. Lowy, M.D., Laboratory of Cellular Oncology, National Cancer Institute, National Institutes of Health, Building 37, Room 4106, MSC 4263, Bethesda, MD 20892 (e-mail: drl{at}helix.nih.gov).
Candidate prophylactic vaccines based on papillomavirus L1 virus-like particles (VLPs) are currently in human clinical trials. The main long-term goal of the vaccine is to reduce the incidence of cervical cancer and its precursors. In animal papillomavirus models, systemic immunization with L1 VLPs can induce high titers of neutralizing antibodies that confer protection against high-dose experimental papillomavirus challenge. In humans, systemic vaccination with L1 VLPs has been well tolerated and induced high serum antibody titers (at least 40 times higher than titers seen following natural infection). A recent proof of principle HPV16 L1 VLP efficacy trial has shown excellent protection against persistent HPV16 infection and associated cytological abnormalities. Large scale efficacy trials of L1 VLPs from HPV16 and 18 (the HPV types found most frequently in cervical cancer), with or without HPV6 and 11 (the HPV types responsible for most genital warts), are planned. If the results of these large trials support the encouraging results of the early trials, they should lead to a commercial prophylactic HPV vaccine. Implementation issues may include how to make the vaccine available in the developing world, where the majority of cervical cancer cases occur, the appropriate age of vaccination, and the role of male vaccination. Because a VLP vaccine is likely to provide type-specific protection, increasing the number of cancer-associated HPV types in the vaccine is a likely approach to broadening the protection to additional types. There will probably also be efforts to develop alternative vaccine formulations better suited to implementation in developing countries as well as attempts to develop vaccines with a therapeutic activity against established HPV infection because a combined prophylactic/therapeutic vaccine may be expected to have an even greater impact than a purely prophylactic vaccine on HPV induced disease.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. L. Hendrix Assessing Human Papillomavirus Vaccine Efficacy and Safety J Am Osteopath Assoc, April 1, 2008; 108(4_suppl_2): S8 - S12. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Mattil-Fritz, D. Scharner, K. Piuko, N. Thones, L. Gissmann, H. Muller, and M. Muller Immunotherapy of equine sarcoid: dose-escalation trial for the use of chimeric papillomavirus-like particles J. Gen. Virol., January 1, 2008; 89(1): 138 - 147. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. G. Ferris Vaccines for Preventing HPV-Related Anogenital Infection and Neoplasia J Am Osteopath Assoc, March 1, 2006; 106(suppl_1): S9 - S13. [Abstract] [Full Text] [PDF]
|
|